Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 14, 2026

Should You Buy, Sell or Hold Amazon (AMZN) Stock at $245?

View original at finance.yahoo.com
“Full-year 2025 revenue came in at $716.92 billion, and the company generated operating income of $79.98 billion across its segments.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bears argue the stock at $240 prices in a best-case AI buildout while underweighting risks that consumer spending softens or enterprise cloud budgets tighten

    60% confidence

  • Amazon holds a Hold rating at $245 as CapEx surge pressures near-term returns

    60% confidence

  • Bulls see three highest-margin segments (AWS, advertising, and third-party services) all accelerating simultaneously

    60% confidence

  • Amazon flagged tariff and trade policy uncertainty, foreign exchange volatility, and recessionary fears as active risks in guidance

    60% confidence

  • Customers wanting to run their AI workloads where the rest of their applications and data are creates a compounding effect, pulling core cloud migration spend alongside AI investment

    60% confidence

Data points we hold from this source

Amazon Web Services · annualized revenue run rate142 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Should You Buy, Sell or Hold Amazon (AMZN) Stock at $245? — Source | Via News | ViaNews EU